2019
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days
2018
Accuracy of electronic health record data for the diagnosis of chronic obstructive pulmonary disease in persons living with HIV and uninfected persons
Crothers K, Rodriguez CV, Nance RM, Akgun K, Shahrir S, Kim J, Hoo G, Sharafkhaneh A, Crane HM, Justice AC. Accuracy of electronic health record data for the diagnosis of chronic obstructive pulmonary disease in persons living with HIV and uninfected persons. Pharmacoepidemiology And Drug Safety 2018, 28: 140-147. PMID: 29923258, PMCID: PMC6309326, DOI: 10.1002/pds.4567.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAge FactorsAlgorithmsBronchodilator AgentsCohort StudiesData AccuracyData Interpretation, StatisticalDrug PrescriptionsElectronic Health RecordsFemaleHIV InfectionsHumansInternational Classification of DiseasesLogistic ModelsMaleMiddle AgedNebulizers and VaporizersPrevalencePulmonary Disease, Chronic ObstructiveRisk FactorsSmokingSpirometryConceptsChronic obstructive pulmonary diseaseICD-9 codesObstructive pulmonary diseaseElectronic health record dataHealth record dataPulmonary diseaseHIV-Associated Lung Emphysema (EXHALE) studyIntegrated Clinical Systems cohortVeterans Aging Cohort StudyHIV uninfected personsAIDS Research NetworkAging Cohort StudyRecord dataEHR dataReceiver-operating curveCohort studyRespiratory symptomsHIV statusUninfected personsClinical variablesDevelopment cohortClinical indicationsSpirometry dataSpirometryUninfected individuals
2011
Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System
Ohl M, Lund B, Belperio PS, Goetz MB, Rimland D, Richardson K, Justice A, Perencevich E, Vaughan-Sarrazin M. Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System. AIDS And Behavior 2011, 17: 250-259. PMID: 22205324, PMCID: PMC5009625, DOI: 10.1007/s10461-011-0107-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCD4 Lymphocyte CountChildChild, PreschoolDelivery of Health CareDiffusion of InnovationFemaleHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHIV Integrase InhibitorsHumansInfantInfant, NewbornMaleMiddle AgedMultivariate AnalysisOdds RatioPatient Acceptance of Health CarePyrrolidinonesRaltegravir PotassiumResidence CharacteristicsRetrospective StudiesRural Health ServicesRural PopulationSurveys and QuestionnairesUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransViral LoadYoung AdultConceptsHIV therapyEqual access healthcare systemNovel HIV therapiesRetrospective cohort studyFirst HIV integrase inhibitorRural-urban variationRaltegravir therapyCohort studyPatient characteristicsMultivariable analysisHIV integrase inhibitorsClinical indicationsRural residenceFDA approvalTherapyIntegrase inhibitorsUrban residenceRural personsHealthcare systemRaltegravirUrban personsDaysRural areasHIVResidence